Professor Steve Jackson is the University of Cambridge Professor of Biology, Head of Cancer Research UK Laboratories at the Gurdon Institute, and Associate Faculty member at the Wellcome Trust Sanger Institute. Steve’s pioneering research over the past twenty years has provided us with key principles by which cells respond to DNA damage.

In 1997, Steve founded the world’s first DDR drug-discovery company, KuDOS, which was acquired by AstraZeneca in 2006. The programmes Steve established and steered within KuDOS (he was CSO 1997-2009) produced compounds that are now widely used as research tools, and several KuDOS-generated compounds are now in AZ-led clinical trials.

In 2010, Steve established MISSION Therapeutics (Babraham, Cambridge) to exploit new drug-discovery and synthetic-lethal therapeutic opportunities arising from his academic work. He serves as part-time CSO for MISSION but spends the majority of his time running his academic research group.